BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Date: Thursday –
The presentation will be webcast live and can be accessed in the investor section (events page) of the BDSI website. For those who are not available to listen to the live broadcast, a replay of the webcast will be available.
About BioDelivery Sciences International, Inc.
BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina.
For more information, please visit or follow us:
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings, and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.
© 2018 BioDelivery Sciences International, Inc. All rights reserved.
Vice President, Investor and Public Relations
Source: BioDelivery Sciences International, Inc.